Delivery Order SPE2DR25D7059-SPE2DR26F7MUL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a ceiling value of $1,867.39. This firm fixed-price delivery order has an ultimate completion date of October 28, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded among...
- The Defense Logistics Agency awarded a $1,033.08 delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count). This competitively awarded, firm fixed-price contract is scheduled for completion by December 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,671.46 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count bottles). This firm fixed-price delivery order, with completion scheduled for December 3, 2025, represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,929.68 to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Losartan-HCTZ 100-25 mg tablets in a 90-day supply. This competitive, firm fixed-price delivery order is scheduled for completion by December 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite Delivery Contract vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) at a ceiling value of $13,135.35. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract has an ultimate completion date of December 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,361.13 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets in a quantity of 90 units. This competitive award, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,850.96 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on December 1, 2025, with an ultimate completion date of December 2, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) with a ceiling value of $1,554.35. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by November 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) with a ceiling value of $11,133.20. The contract, which is a firm fixed-price delivery order without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. This pharmaceutical supply order will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,289.56 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets in quantities of 90 units. This competitively awarded, firm fixed-price delivery order was issued on November 25, 2025, with an ultimate completion date of November 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal...
- SPE2DR25D7059Indefinite Delivery Contract
- SPE2DR25D7059-SPE2DR26F7MULDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,652.50 to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count). This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of December 10, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement from DLA's medical supply chain to support federal healthcare needs. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp leverages this comprehensive IDC to supply a broad range of pharmaceuticals and medical commodities to support military healthcare systems, the Defense Health Agency, and other federal customers globally. The company's extensive contract portfolio with DLA demonstrates its capability to consistently meet federal procurement requirements across diverse therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 12/8/25 |